Vmbook Online ordering

Response Genetics Inc

Response Genetics, Inc. (RGDX) was a publicly traded company that focused on the development and commercialization of molecular diagnostic tests for cancer and other diseases. The company was listed on the NASDAQ stock exchange under the ticker symbol "RGDX." Unfortunately, Response Genetics was acquired by another company in 2015, so the ticker symbol is no longer active. However, I can still provide some general information about the company'

Response Genetics was incorporated in 1999 and was headquartered in Los Angeles, California. The company's main focus was on developing and commercializing molecular diagnostic tests for cancer and other diseases. These tests were designed to help physicians make more informed treatment decisions by providing critical information about the genetic characteristics of a patient's disease.

In terms of earnings, Response Genetics had consistently generated net losses over the years. In 2014, the company reported a net loss of $38.5 million, compared to $21.5 million in 2013. The company's revenue had also been declining, with $14.3 million in revenue reported in 2014, down from $16.7 million in 2013.

One of the company's lead products was the ResponseDX: Lung CDx, a molecular diagnostic test designed to help physicians identify non-small cell lung cancer patients who are likely to benefit from treatment with a specific class of drugs called tyrosine kinase inhibitors. The company also had other products in development for various types of cancer, including melanoma, breast, and colon cancer.

In terms of growth, the company had made significant investments in research and development to expand its product offerings and increase its market share in the molecular diagnostics market. In 2014, the company received FDA approval for its melanoma test, which was seen as a significant growth opportunity.

However, as mentioned, in 2015, the company was acquired by another company called Veracyte, Inc., which is also a molecular diagnostics company. Veracyte has continued to develop and commercialize the Response Genetics' products, including the ResponseDX:Lung CDx test.

Overall, Response Genetics was a development-stage company that focused on the development and commercialization of molecular diagnostic tests for cancer and other diseases. While the company had reported net losses in its history, it had a promising product pipeline and had made significant investments in research and development to drive future growth. Unfortunately, since its acquisition, the company's stock symbol is no longer active.

However, the products they were developing and commercializing are still in use today and are helping many physicians and patients.

I hope that was helpful. Please let me know if there's anything specific you'd like to ask about this company.